Kawai T, Poncelet A, Sachs D H, Mauiyyedi S, Boskovic S, Wee S L, Ko D S, Bartholomew A, Kimikawa M, Hong H Z, Abrahamian G, Colvin R B, Cosimi A B
Department of Surgery, Harvard Medical School at Massachusetts General Hospital, Boston 02114, USA.
Transplantation. 1999 Dec 15;68(11):1767-75. doi: 10.1097/00007890-199912150-00022.
Multilineage chimerism and long-term acceptance of renal allografts has been produced in non-human primates conditioned with a nonmyeloablative regimen. Our study was undertaken to evaluate the immunological and pathological status of long-term survivors and to define the role of splenectomy and of the primarily vascularized kidney in the regimen.
Monkeys were treated with the basic regimen, including: total body irradiation, thymic irradiation, antithymocyte globulin, donor bone marrow transplantation, and a 4-week course of cyclosporine after which no further immunosuppression was given. They were divided into four groups according to the timing of kidney transplantation (KTx) and splenectomy as follows; group A (n=13): KTx and splenectomy on the day of donor bone marrow transplantation (day 0); group B (n=3): KTx on day 0 without splenectomy; group C (n=7): splenectomy on day 0 but delayed KTx until 3 to 16 weeks post-donor bone marrow transplantation; group D (n=3): both splenectomy and KTx delayed until day 120 post-donor bone marrow transplantation.
In group A, 11 of 13 monkeys developed chimerism and 9 monkeys achieved long-term survival of 4 to 70 months without evidence of chronic vascular rejection. Alloantibodies were detected in only one long-term survivor. In contrast, all three monkeys in group B developed alloantibodies and rejected their allografts. In group C, long-term survival without alloantibody production was observed in two of three monkeys that had developed chimerism. In group D, all three recipients were sensitized and rejected the kidney allografts rapidly after transplantation.
采用非清髓性方案预处理的非人灵长类动物已实现肾移植的多谱系嵌合及长期存活。我们开展本研究以评估长期存活者的免疫和病理状态,并确定脾切除术及带血管蒂肾在该方案中的作用。
猴子接受基础方案治疗,包括:全身照射、胸腺照射、抗胸腺细胞球蛋白、供体骨髓移植,以及为期4周的环孢素治疗,之后不再给予进一步免疫抑制。根据肾移植(KTx)和脾切除术的时间将它们分为四组,如下:A组(n = 13):在供体骨髓移植当天(第0天)进行KTx和脾切除术;B组(n = 3):在第0天进行KTx但未行脾切除术;C组(n = 7):在第0天进行脾切除术,但将KTx推迟至供体骨髓移植后3至16周;D组(n = 3):脾切除术和KTx均推迟至供体骨髓移植后第120天。
A组中,13只猴子中有11只出现嵌合现象,9只猴子实现了4至70个月的长期存活,且无慢性血管排斥的证据。仅1名长期存活者检测到同种抗体。相比之下,B组的3只猴子均产生了同种抗体并排斥了它们的移植肾。C组中,在出现嵌合现象的3只猴子中,有2只观察到长期存活且未产生同种抗体。D组中,所有3名受者均被致敏,并在移植后迅速排斥了肾移植。
1)在供体骨髓移植时行脾切除术的方案中,大多数出现混合嵌合的受者可预防抗供体抗体的产生。2)如果初始预处理方案中不包括脾切除术,则诱导B细胞耐受的可能性较小,结果是同种抗体产生延迟和移植肾排斥。3)在受者预处理时立即进行肾移植对于通过骨髓移植诱导供体特异性低反应性并非必不可少。